Leading Contract Research Organizations and Their Employees Contribute More Than $670,000 to Disaster Relief Efforts
WASHINGTON, D.C., December 21, 2001 — Leading companies that provide contract research services for the pharmaceutical and biotechnology industries have contributed more than $670,000 to help aid victims of the September 11 terrorist attacks and their families. The money was raised through employee contributions and company matching funds.
"Members of our industry share the common goal of helping our pharmaceutical and biotechnology partners improve health and save lives around the world. This collective relief effort aligns with our commitment to reduce human suffering caused by disease and illness, and we're proud that our employees have stepped forward to assist those in need following the disasters of September 11," said Douglas Peddicord, Ph.D., on behalf of the five global contract research organizations, or CROs.
The CROs supporting relief efforts include Covance Inc., Kendle International Inc., PAREXEL International Corp., PPD, Inc., and Quintiles Transnational Corp. Among the charitable organizations receiving contributions are: American Red Cross Disaster Relief Fund, New York Firefighters 9-11 Disaster Relief Fund, New York Police and Fire Widows and Children's Benefit Fund, The September 11th Fund, The Survivors Fund of the National Capitol Region, Twin Towers Fund, Uniformed Firefighters Association Widows and Children's Fund, and the United Way.
Each of the CROs involved in the disaster support effort provides a wide range of research and development services that help pharmaceutical and biotechnology companies bring medicines to patients quickly and safely. These five CROs employ approximately 36,000 people worldwide and conduct research in 60 countries.
SOURCE: Covance Inc.; Kendle International Inc.; PAREXEL International Corp.; PPD, Inc.; Quintiles Transnational Corp.
CONTACT: Douglas Peddicord, +1-202-543-7460